Probi AB (OSTO:PROB) Common Stock : kr58.2 Mil (As of Mar. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Probi AB Common Stock?

Probi AB's quarterly common stock stayed the same from Sep. 2023 (kr58.2 Mil) to Dec. 2023 (kr58.2 Mil) and stayed the same from Dec. 2023 (kr58.2 Mil) to Mar. 2024 (kr58.2 Mil).

Probi AB's annual common stock stayed the same from Dec. 2021 (kr58.2 Mil) to Dec. 2022 (kr58.2 Mil) and stayed the same from Dec. 2022 (kr58.2 Mil) to Dec. 2023 (kr58.2 Mil).

Probi AB Common Stock Historical Data

The historical data trend for Probi AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Probi AB Common Stock Chart

Probi AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

58.22

Probi AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															58.22	58.22	58.22	58.22	58.22

Probi AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Probi AB (OSTO:PROB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Probi AB (OSTO:PROB) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

PBBIF:USA

Address

Ideongatan 1 A, Lund, SWE, SE-223 70

Website

https://www.probi.com

Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. The company's research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).

Probi AB (OSTO:PROB) Headlines

No Headlines